NCT06501599 AI-based System for Assessing Suspected Viral Pneumonia Related Lung Changes
| NCT ID | NCT06501599 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department |
| Condition | Pneumonia, Viral |
| Study Type | OBSERVATIONAL |
| Enrollment | 563 participants |
| Start Date | 2024-06-03 |
| Primary Completion | 2025-06-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 563 participants in total. It began in 2024-06-03 with a primary completion date of 2025-06-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The AI-based system designed to process chest computed tomography (CT) aims to 1) detect the presence of pathologic patterns associated with interstitial changes in pneumonia; 2) highlight areas on the images with the probable presence of pathologies; 3) provide the physician with the results of image processing, including quantitative indicators of suspected viral pneumonia related lung changes according to visual pulmonary lesion grading system (CT0-4). The retrospective study aims to demonstrate the clinical validation of the AI-based system. Clinical validation measures (sensitivity, specificity, accuracy, and area under the ROC curve) will be determined to provide evidence about the clinical efficacy of the AI-based system. The hypothesis is that the measures of clinical validation of the AI-based system differ by no more than 8% from those declared by the manufacturer.
Eligibility Criteria
Inclusion Criteria: 1. General 1. Patients over 18 years old; 2. Patients who underwent CT without contrast enhancement; 3. Patients who underwent a CT scan according to a standardized scanning protocol: 120 kilovolts, slice thickness max. 2 mm, rigid "lung" filter (kernel) reconstruction; 4. Patients whose studies should be of acceptable quality, performed with breath-holding, without technical artifacts, and respiratory and motor artifacts; 5. Patients whose studies must contain DICOM tags responsible for the orientation and position of the patient in the images during the study, as well as DICOM tags responsible for the size of the scans and image parameters; 6. Patients in whom the localization of changes is predominantly bilateral, in the basal and subpleural parts of the lungs, may be located peribronchial; 2. For group Normal a. Patients who do not contain COVID-19-related CT patterns; 3. For groups Mild, Moderate, Severe, and Critical 1. Patients who contain COVID-19-related CT pattern: ground glass opacities (mild, moderate, and higher intensity); 2. Patients who contain COVID-19-related CT pattern: pulmonary consolidation; 3. Patients who contain COVID-19-related CT pattern: cobblestone infiltration of the lung parenchyma; 4. Patients who contain COVID-19-related CT pattern: hydrothorax; 5. Patients who contain a combination of one or more patterns. Exclusion Criteria: * Patients whose studies contain images with unreported CT patterns; * Patients whose examinations do not conform to DICOM format; * Patients whose examinations do not contain imaging of the lung region * Patients whose examinations contain technical artifacts caused by malfunctions or features of CT scanners; * Patients whose examinations contain improper patient positioning; * Patients whose examinations contain studies with deleted DICOM tags responsible for scan size and image parameters; * Patients whose examinations contain metal artifacts on the patient's body and clothing; * Patients whose examinations contain the presence of other pathologic changes of lungs in patients - neoplastic, tuberculosis process, bacterial pneumonia, etc.; * Patients under 18 years old.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06501599 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pneumonia, Viral. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06501599 currently recruiting?
Yes, NCT06501599 is actively recruiting participants. Contact the research team at ZinchenkoVV1@zdrav.mos.ru for enrollment information.
Where is the NCT06501599 trial being conducted?
This trial is being conducted at Moscow, Russia.
Who is sponsoring the NCT06501599 clinical trial?
NCT06501599 is sponsored by Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department. The trial plans to enroll 563 participants.